Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17761311 | 0.98 | HSD11B1 (0.71) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL6494518 | 0.95 | HSD11B1 (0.68) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL17761217 | 0.95 | HSD11B1 (0.66) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL6499750 | 0.94 | HSD11B1 (0.65) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL17761233 | 0.91 | HSD11B1 (0.60) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12836593 | 0.83 | SLC6A3 (0.62) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17761201 | 0.83 | HSD11B1 (0.51) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL10695332 | 0.83 | HSD11B1 (0.73) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL6491320 | 0.83 | HSD11B1 (0.51) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17761202 | 0.83 | DPP4 (0.56) | HSD11B1SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | HSD11B1 1180/4885SLC6A3 167/4885SLC6A4 288/4885 |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | HSD11B1 1180/4885SLC6A3 167/4885SLC6A4 288/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | HSD11B1 1367/4885SLC6A3 163/4885SLC6A4 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.